Page 2 - Andrew Hack News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The community at Wye River faces a choice about how to protect the beach and surf life-saving club.

/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today...

/PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today...

Cambridge cancer drug startup Nuvalent raises $135 million The new funding comes just four months after it was launched with $50 million. By Jonathan Saltzman Globe Staff,Updated May 11, 2021, 6:00 a.m. Email to a Friend James Porter is CEO of Cambridge biotech Nuvalent.Nuvalent Nuvalent, a Cambridge biotech working on precision cancer drugs, has raised another $135 million in venture capital just four months after the firm was launched with $50 million in financing. The startup is developing lung cancer drugs that rely on enzyme blockers known as kinase inhibitors to help keep cancer cells f...

Nuvalent, Inc., a Cambridge, Mass.-based biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, closed a $135m Series B financing. The round was led by Bain Capital Life Sciences with participation from sole founding investor, Deerfield Management, and additional new investors Fidelity Management and Research Company LLC, Wellington Management Company, Viking Global Investors, Janus Henderson Investors, Avoro Capital Advisors, Boxer Capital of Tavistock Group, Venrock Healthcare Capital Partners, Fairmount Funds Management LLC, Driehaus C...